Microbix Biosystems (TSE:MBX) Announces Earnings Results

Microbix Biosystems (TSE:MBX) released its earnings results on Thursday. The company reported C($0.01) EPS for the quarter, FiscalAI reports. The business had revenue of C$3.38 million for the quarter. Microbix Biosystems had a negative return on equity of 14.88% and a negative net margin of 25.48%.

Here are the key takeaways from Microbix Biosystems’ conference call:

• Q2 results were weak, with revenues below the company’s breakeven level and a net loss, driven mainly by lower sales to China and a soft quarter for QAPs.
• Excluding the China distributor decline, the company said the rest of the business grew 13% in the quarter, while management emphasized that new large customer opportunities are building.
• Management reiterated that the balance sheet remains strong, with CAD 8.1 million in cash and expected quarterly cash burn around CAD 1 million including debt repayment, CapEx, and share buybacks.
• The company said its operational capabilities and capacity have been significantly expanded, supporting large audits from major customers and positioning Microbix for larger-scale business wins.
• Kinlytic remains on track toward a supplemental biologics filing in 2027 and a market launch in 2028, with management describing strong demand potential and ongoing manufacturing/validation work with Sequel.

Microbix Biosystems Trading Down 11.8%

Shares of MBX stock traded down C$0.03 during trading hours on Friday, hitting C$0.23. 65,000 shares of the company were exchanged, compared to its average volume of 61,096. The company has a debt-to-equity ratio of 30.47, a quick ratio of 5.57 and a current ratio of 7.51. The firm has a market cap of C$31.17 million, a P/E ratio of -7.50 and a beta of 0.48. The company has a 50 day simple moving average of C$0.24 and a two-hundred day simple moving average of C$0.24. Microbix Biosystems has a fifty-two week low of C$0.21 and a fifty-two week high of C$0.36.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.